objective To observe the efficacy and side effects of autologous cytokine-induced killer cells ( CIK cells) and dendritic cells (DC) and Sorafenib in the treatment of metastatic renal cell carcinoma ( mRCC). Methods DC and CIK cells were amplified in peripheral blood. Flow cytometry was used to detect CIK, DC-CIK phenotype, and then taking intravenous transfusion method to treat the mRCC patients with autologous CIK, DC and Sorafenib. Results In 26 cases of patients, there were one patient with complete remission, 4 ones with partial remission, 17 ones with stability, 4 ones with disease progression. The rate of disease control is 72. 7% , and the objective effective power is 19. 2%. Median survival time was 25 months, and the lack of progress in time(mPFS) was 14 months. Main side effects were rash, diarrhea, fever, fatigue, flu-like symptoms, anorexia, reduced body mass, and neutrocytopenia, etc. Referenced to the risk factors for prognosis of layered model MSKCC score, RR in the low risk of group was higher than that in the high risk group ( P < 0.05). The MST among low, medium and high risk groups had significant differences(P = 0.000). Conclusion Autologous DC and CIK cells combined with Sorafenib in treating mRCC patients has a acceptable curative effect, and tolerated side effects.%目的 观察转移性肾细胞癌(mRCC)患者行自体细胞因子诱导的杀伤细胞(CIK细胞)及树突状细胞(DC)联合索拉非尼治疗的临床疗效及不良反应.方法 用患者自体外周血进行CIK细胞及DC细胞扩增,并应用流式细胞术检测其CIK、DC-CIK表型,然后采取静脉回输方法,对mRCC患者进行自体CIK细胞及DC细胞联合索拉非尼治疗.结果 26患者中,完全缓解1例,部分缓解4例,疾病稳定17例,疾病进展4例,疾病控制率72.7％;客观有效率19.2％.中位生存时间为25个月,中位无进展时间14个月.主要不良反应为皮疹、腹泻、发热、乏力、流感样症状、厌食、体质量下降和中性粒细胞减少等.参照预后分层模型MSKCC危险因素评分,低危组的RR高于高危组(P＜0.05),低、中、高危组的中位生存时间有统计学差异(P=0.000).结论 自体CIK细胞及DC联合索拉非尼治疗mRCC患者疗效尚可,毒副反应可耐受.
展开▼
